Land: Indonesien
Språk: indonesiska
Källa: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
MESALAZINE
ABBOTT INDONESIA - Indonesia
MESALAZINE
1 G
ENEMA
DUS, 7 BOTOL PLASTIK @ 100 ML
FERRING-LECIVA, A.S - Czech Republic
2020-02-09
PROPOSED PACKAGING MATERIAL Code PENSUS-I-ID-02.02 Size NA Submission ☐ NDA ☐ Renewal ☒ Variation change detail no.: CR 129438, 165591, 148998 Code of previous version PENSUS-I-ID-01.01 Changes BPOM Deficiency letter date 19Mar2021 (Revision on contraindication and interactions) Reference ☒ CCDS version: CCDS Ver.17 (Jan 2021) ☐ Core PIL version: ☐ SPC country/version/date: ☐ LAC no.: Name & Date IRM, 07-Dec-2021 1 PENTASA ® MESALAZINE Enema 1g COMPOSITION Each enema contains 1 g mesalazine. Excipients: Disodium edetate, sodium metabisulphite, sodium acetate, purified water, hydrochloric acid for pH adjustment. PHARMACEUTICAL DOSAGE FORM Enema (rectal suspension) White to slightly yellow suspension with a pH value between 4.4 and 5.0. INDICATIONS Treatment of mild to moderate ulcerative proctosigmoiditis POSOLOGY AND METHOD OF ADMINISTRATION _Posology: _ 1 enema at bedtime _ _ _Paediatric population: _ Not recommended _ _ _Method of administration: _ A visit to the toilet is recommended before administration of enemas. _Instructions for use: _ Shake the enema container well before use. The enema is protected by an aluminium foil bag and should be used immediately after opening of the bag. The enema may colour the linen and toilet. CONTRAINDICATIONS Hypersensitivity to mesalazine, any of the excipients, or salicylates. Severe liver or renal impairment. SPECIAL WARNINGS AND PRECAUTIONS FOR USE Most patients who are intolerant or hypersensitive to sulphasalazine are able to take PENTASA without risk of similar reactions. However, caution is recommended when treating patients allergic to sulphasalazine (risk of allergy to salicylates). Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment. In case of acute intolerance reactions such as abdominal cramps, acute abdominal pain, fever and severe headache and/or the first appearance of signs and symptoms of severe skin reactions, such as Läs hela dokumentet